How Much Did CroíValve Raise?
Funding & Key Investors

CroíValve, a pioneer in the development of minimally invasive cardiovascular solutions, has successfully secured a major strategic investment, bringing its total capital accumulation to $64.8M. This latest infusion of $36M underscores the market confidence in the company's proprietary DUO System, a technology engineered to address the critical clinical gap in treating tricuspid regurgitation. By securing this significant financing, CroíValve is well-positioned to accelerate its clinical development trajectory and navigate the complex regulatory landscape required for commercialization in the United States and European markets.

The company's growth trajectory has been marked by a series of strategic funding rounds, beginning with its initial seed capital in 2019 and culminating in this recent Series B milestone. This progression reflects a disciplined approach to capital allocation, moving from early-stage research and development to the current phase of intensive clinical investigation. The backing of both institutional venture capital and government-backed innovation agencies highlights the systemic importance of the DUO System in addressing a condition that affects millions of patients globally.